P832 Cannabis Use in IBD Patients: A Population-Based Study

Dasu, N.(1)*;John, J.(2);Blair, B.(3);Khalid, Y.(4);Walters, R.(3);Chhoun, C.(2);Suga, H.(3);

(1)Jefferson Health New Jersey, Gastroenterology, NJ, United States;(2)Jefferson Health NJ, Internal Medicine, Cherry Hill, United States;(3)Jefferson Health NJ, Gastroenterology, Cherry Hill, United States;(4)Wright Center for GME/Geisinger Health, Cardiology, Scranton, United States;


Inflammatory Bowel Disease (IBD) leads to a chronic inflammatory state in the body with significant long-term impact on patient morbidity and mortality. This study investigates the inpatient hospitalization outcomes in patients with IBD with the concurrent utilization of cannabis compared to IBD patients without a concurrent diagnosis to indicate cannabis usage. 


The Nationwide Inpatient Sample (NIS) database encompasses approximately 7 million inpatient hospitalizations annually in the United States. Data were extracted from the National Inpatient Sample (NIS) Database for the years 2015-2019. Patients aged 18 years and above with diagnoses of IBD with concurrent cannabis use were identified. Multivariate regression analysis was used to estimate the odds ratios of in-hospital mortality, the average length of hospital stay (LOS), and hospital charges using STATA 17.  Multivariate logistic and linear regression analysis was used accordingly to adjust for confounders.


We identified 1,198,839 patients with IBD of which 29,445 were matched to those with cannabis use. The average age was 38.67 years. There was a significant decrease in inpatient mortality  (OR 0.28, CI 0.19-0.41, p<0.0001), hospital length of (-0.17 days CI -0.35 -0.01, p<0.041), and total cost of hospitalization (-$11,054.70, CI -13,681.15 - -8427.24, p<0.0001) between patients with IBD with cannabis use when compared to IBD patients without cannabis use.


This study demonstrates a significant decrease in mortality rate, cost of hospitalization, and length of stay in IBD patients with concurrent diagnoses to indicate cannabis usage. This study shows that there are substantial therapeutic effects of cannabis in the management of patients with IBD. Further studies are warranted to investigate the factors that may be driving these differences. Future arms of investigation would be warranted to investigate the effect of cannabis on remission rates, rates of hospitalization, and patient Mayo Endoscopic Scores and Simple Endoscopic Scores for Crohn’s disease.